SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
CONMED Corporation (CNMD) trades at a trailing P/E of 24.2, forward P/E of 9.1. Trailing earnings yield is 4.13%, forward earnings yield 11.04%. PEG 0.05 (Peter Lynch undervalued ≤1.0). Graham Number is $33.77.
Criteria proven by this page:
- VALUE (74/100, Pass) — P/E is below market average (24.2); PEG ≤ 1.0 — Peter Lynch undervalued (0.05); analyst target implies upside (+97.8%); earnings yield beats bond yields (4.13%).
- Forward P/E 9.1 (down from trailing 24.2) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.05 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 4.13% — roughly competitive with bond yields (~4.3%), moderate risk-reward. Forward yield improves to 11.04% as earnings recover.
- Analyst consensus target $78.00 (+97.8% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 64/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
74/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — CNMD
Valuation Multiples
P/E (TTM)24.2
Forward P/E9.1
PEG Ratio0.05
Forward PEG0.05
P/B Ratio1.10
P/S Ratio0.83
EV/EBITDA11.0
Per Share Data
EPS (TTM)$1.52
Forward EPS (Est.)$4.36
Book Value / Share$33.36
Revenue / Share$44.39
FCF / Share$4.87
Yields & Fair Value
Earnings Yield4.13%
Forward Earnings Yield11.04%
Dividend Yield1.09%
Graham Number$33.77
SharesGrow IV$153.11 (+288.2%)
Analyst Target$78.00 (+97.8%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
83.7 |
-1.62 |
2.12 |
1.61 |
1.81% |
| 2017 |
25.7 |
0.09 |
2.26 |
1.79 |
1.57% |
| 2018 |
44.2 |
-1.63 |
2.73 |
2.10 |
1.24% |
| 2019 |
110.7 |
-3.65 |
4.46 |
3.32 |
0.71% |
| 2020 |
336.4 |
-5.00 |
4.51 |
3.71 |
0.71% |
| 2021 |
66.1 |
0.12 |
5.26 |
4.09 |
0.56% |
| 2022 |
-33.0 |
0.15 |
3.57 |
2.55 |
0.90% |
| 2023 |
52.1 |
-0.29 |
4.03 |
2.70 |
0.73% |
| 2024 |
15.9 |
0.15 |
2.19 |
1.62 |
1.17% |
| 2025 |
26.8 |
-0.41 |
1.22 |
0.92 |
1.96% |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$0.52 |
$763.52M |
$14.66M |
1.9% |
| 2017 |
$1.97 |
$796.39M |
$55.49M |
7% |
| 2018 |
$1.41 |
$859.63M |
$40.85M |
4.8% |
| 2019 |
$0.97 |
$955.1M |
$28.62M |
3% |
| 2020 |
$0.32 |
$862.46M |
$9.52M |
1.1% |
| 2021 |
$1.94 |
$1.01B |
$62.54M |
6.2% |
| 2022 |
$-2.68 |
$1.05B |
$-80.58M |
-7.7% |
| 2023 |
$2.04 |
$1.24B |
$64.46M |
5.2% |
| 2024 |
$4.26 |
$1.31B |
$132.42M |
10.1% |
| 2025 |
$1.51 |
$1.37B |
$47.06M |
3.4% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$4.36 |
$4.34 – $4.37 |
$1.36B |
$1.35B – $1.37B |
3 |
| 2027 |
$4.93 |
$4.84 – $5.09 |
$1.43B |
$1.42B – $1.44B |
3 |
| 2028 |
$5.55 |
$5.49 – $5.62 |
$1.52B |
$1.52B – $1.52B |
1 |
